PNC-27 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Demonstrated efficacy against breast, pancreatic, lung, colon, ovarian, and leukemia cancer cells ex vivo. Research spans 2008-2024 with consistent findings of cancer cell selectivity. Clinical trials conducted outside USA reportedly successful. No US clinical trials. PNC-27 is not fda-approved in usa. clinical trials conducted internationally. research use only in us.
What Does the Research Say About PNC-27?
Demonstrated efficacy against breast, pancreatic, lung, colon, ovarian, and leukemia cancer cells ex vivo. Research spans 2008-2024 with consistent findings of cancer cell selectivity. Clinical trials conducted outside USA reportedly successful. No US clinical trials.
PNC-27 (PNC-27 (p53-penetratin chimeric peptide)) is a Cell-penetrating therapeutic peptide. Research interest has focused on its potential effects on broad-spectrum cancer cell killing, p53-independent mechanism, minimal normal cell toxicity, rapid killing kinetics (90 minutes).
What Is the Evidence for PNC-27's Mechanism?
Binds to HDM-2 on cancer cell plasma membranes (residues 1-109), inducing transmembrane pore formation and necrosis. Additionally penetrates cancer cells and disrupts mitochondrial membranes, causing apoptosis. Kills cancer cells regardless of their p53 mutation status.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for PNC-27?
Demonstrated efficacy against breast, pancreatic, lung, colon, ovarian, and leukemia cancer cells ex vivo. Research spans 2008-2024 with consistent findings of cancer cell selectivity. Clinical trials conducted outside USA reportedly successful. No US clinical trials.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, PNC-27 has shown encouraging results.
What Does the Safety Research Show?
Limited safety data. No apparent toxicity to normal tissue in culture. Potential immune responses to foreign peptide.
PNC-27 is not fda-approved in usa. clinical trials conducted internationally. research use only in us.
What Makes PNC-27 Unique in Research?
P53-independent killing mechanism works even on cancers where p53 is mutated (a common tumor escape route) — combined with 90-minute killing kinetics, this is one of the most potent anti-cancer peptides ever characterized.
This differentiator is important because it means PNC-27 fills a role that other compounds in its class may not fully replicate.
Bottom Line on PNC-27 Research
The evidence base for PNC-27 is growing. Key research areas include broad-spectrum cancer cell killing, p53-independent mechanism, minimal normal cell toxicity, rapid killing kinetics (90 minutes).
Stay current with PubMed searches for PNC-27 for the latest publications.
Complete Guide
PNC-27 : Benefits, Dosage, Side Effects & Research
Related Reading
Calculate Your PNC-27 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PNC-27.
Open Calculator →Research-Grade Sourcing
If you're going to research PNC-27, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PNC-27?
PNC-27 (PNC-27 (p53-penetratin chimeric peptide)) is a Cell-penetrating therapeutic peptide. 32-residue chimeric peptide combining an HDM-2 binding domain from p53 with a cell-penetrating penetratin sequence. It is researched for broad-spectrum cancer cell killing, p53-independent mechanism, minimal normal cell toxicity, rapid killing kinetics (90 minutes).
What is the recommended PNC-27 dosage?
Common dosages: >10 mcg/mL (in vitro effective concentration); clinical dosing not established administered not established for human use via local application (proposed: nebulizer, suppository, IV at tumor site). Cycle length: unknown; 90-minute killing kinetics in vitro. Half-life: not established. Use our peptide calculator for exact reconstitution math.
What are the side effects of PNC-27?
Limited safety data. No apparent toxicity to normal tissue in culture. Potential immune responses to foreign peptide.
Is PNC-27 safe?
PNC-27 has shown a preliminary safety profile in research. Not FDA-approved in USA. Clinical trials conducted internationally. Research use only in US. All research should follow appropriate safety protocols.